Hillstream BioPharma, a biotechnology company specializing in the development of innovative treatments for drug-resistant cancers, has recently announced a strategic reprioritization of its pipeline. The focus will now shift towards targeting HER2/HER3 solid tumors using bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs).
The company's lead bispecific antibody, HSB-3215, is specifically designed to target unique conformational epitopes on both HER2 and HER3. This novel approach aims to enhance the Bystander Effect, ultimately increasing the effectiveness of ADCs in eliminating cancer cells.
In order to successfully implement this new strategy, Hillstream BioPharma will be taking decisive action by...